Sort   by:  
 Page size 
UnknownLoss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study.
Not available
S-EPMC7731769 | biostudies-literature
UnknownNon-imported malaria in Italy: paradigmatic approaches and public health implications following an unusual cluster of cases in 2017.
Not available
S-EPMC7275312 | biostudies-literature
UnknownEfficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study.
Not available
S-EPMC5610019 | biostudies-literature
UnknownSafety and Efficacy of Ribociclib in Combination with Letrozole in Patients with HR+, HER2- Advanced Breast Cancer: Results from the Italian Subpopulation of Phase 3b CompLEEment-1 Study.
Not available
S-EPMC9684264 | biostudies-literature
UnknownTolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study.
Not available
S-EPMC9615373 | biostudies-literature
UnknownThe prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial.
Not available
S-EPMC8253801 | biostudies-literature
UnknownT-DM1 versus pertuzumab, trastuzumab and a taxane as first-line therapy of early-relapsed HER2-positive metastatic breast cancer: an Italian multicenter observational study.
Not available
S-EPMC8047485 | biostudies-literature
ProteomicsMStern Blot - Urinary Biomarker Study
This large-scale study focused on the discovery on urinary biomarker for ovarian cyst.
ORGANISM(S): Homo Sapiens (ncbitaxon:9606) 
2017-04-01 | MSV000080874 | MassIVE
UnknownSNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 Trials.
Not available
S-EPMC10722129 | biostudies-literature
UnknownDistinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.
Not available
S-EPMC7027476 | biostudies-literature
Sort   by:  
 Page size